Navigation Links
Nucletron Increases Full Year Outlook After Strong First Half 2009
Date:9/3/2009

VEENENDAAL, the Netherlands, September 3 /PRNewswire/ --

- Despite Challenging Global Economic Conditions, Nucletron Surpassed Projections for the First Half Year

Nucletron, a global leader in radiation oncology, today announced strong financial results over the first half year of 2009. Despite challenging global economic conditions, Nucletron surpassed projections for the first half year.

Net sales amounted to EUR 51.2 million, a 3% growth on like-for-like basis compared to the first half of 2008. EBITDA in the first half of 2009 amounted to EUR 6.3 million, a 53% increase compared to EUR 4.1 million over the same period last year. As a result of the positive developments Nucletron expects full year EBITDA to increase to EUR 19.0 million.

Jos Lamers, chief executive officer of Nucletron, comments: "Over the first six months of 2009, we have seen the results of our improved focus on innovation and our increased marketing efforts. Our senior management team is at full strength after the appointment of three new team members with a blue chip background. Combining our strength in marketing and sales with the research & development capabilities of Isodose Control will make Nucletron one of the global leaders in brachytherapy. Given our many upcoming product releases in the months ahead, we are on track to outperform our 2009 goals."

Among the several advancements made in the first half of 2009, Nucletron partnered with Advanced Radiation Therapy (ART) to offer a revolutionary solution for treating breast cancer. AccuBoost allows clinicians to use image-guidance, as used in a standard mammography, to pinpoint radiation directly to the tumour site. This allows for much better accuracy in targeting the radiation to the cancerous area, while protecting the patients' healthy organs during treatment.

The business collaboration with Isodose Control is now in place. The partnership allows clinicians to benefit from Nucletron's leadership and strength in brachytherapy with Isodose Control's track record of innovation.

Additionally, Nucletron launched its latest evolution in treatment planning for radiotherapy. Model-based segmentation in Oncentra MBS and volumetric modulated arc therapy with Oncentra VMAT ensure quality, while dramatically reducing the time needed to create treatment plans.

Visit our website http://www.nucletron.com

About Nucletron

Nucletron is a global leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians.


'/>"/>
SOURCE Nucletron B V
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
2. Nucletron and Advanced Radiation Therapy (ART) Jointly Announce a Global, Strategic Partnership to Offer AccuBoost(R) for Image-Guided Breast Irradiation
3. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
4. Fat on chest and upper back increases risk of insulin resistance
5. Handling Stress Properly Increases Good Cholesterol
6. High alcohol consumption increases stroke risk among Chinese men
7. High alcohol consumption increases stroke risk, Tulane study says
8. Genetic predisposition increases childhood asthma risk
9. Smoking increases risks for head and neck cancers for men and women
10. Passive smoking increases sleep disturbance among pregnant women
11. Frequent alcohol consumption increases cancer risk in older women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... a clinician-based audience, will be participating in Rare Disease Day events, hosted by ... In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... leadership , media relations, content marketing, social media management, corporate communications, SEO and ... in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC announces ... and explore the world from different perspectives. By providing a place for people ... understanding, increase empathy, and find greater happiness. , "Our approach to structuring ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism and ... for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. ... to see films in an environment that accommodates their unique needs. , Launched ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the Blüm ... in children aged 3-8 with Autism, is now enrolling at three new sites. These ... the United States. , “There are currently no approved drugs that address the ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)... Feb 24, 2017 Medivir AB ... for a new Board of Directors that will be ... Nomination Committee comprises representatives of the company,s three largest ... 2016 who have accepted a seat on the Nomination ... of the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... Research and Markets has announced the addition ... - 2016" report to their offering. ... The latest research Autism Spectrum Disorder ... and benchmarks in the global Autism Spectrum Disorder market. The ... are the key drugs marketed for Autism Spectrum Disorder and their ...
Breaking Medicine Technology: